How our immune system’s “brakes” help balance allergy and infection
🏅 2025 Nobel Prize in Medicine: Celebrating a Breakthrough in Immune Regulation
On 6 October 2025, the Nobel Prize in Physiology or Medicine was awarded to Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi for discovering regulatory T cells (Tregs) and the FOXP3 gene — the master switch that controls immune tolerance.
Their work revealed how the immune system prevents itself from attacking the body’s own tissues. This discovery has since guided the development of immune-modulating therapies now used in cancer, autoimmune, and allergic diseases.
This Nobel recognition highlights how understanding Tregs can lead to smarter, safer therapies — including future immune-based treatments for Allergic Bronchopulmonary Aspergillosis (ABPA) and Chronic Pulmonary Aspergillosis (CPA), where immune balance is disrupted.
🔍 What Are Regulatory T Cells?
Regulatory T cells (Tregs) are a specialised group of white blood cells (lymphocytes) that act as the “brakes” of the immune system.
They prevent excessive inflammation and protect the body from overreacting to harmless particles such as dust, pollen, or Aspergillus spores.
Tregs work by releasing interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β), two powerful calming signals that suppress over-active helper T cells (Th2 and Th17) and reduce allergic or inflammatory damage.
🦠Aspergillus and the Immune System
Everyone inhales Aspergillus spores daily.
In healthy people, the immune system quickly clears them. But in individuals with asthma, allergies, or lung damage, the immune response can become unbalanced:
| Form of Aspergillosis | Main Immune Problem | Treg Function |
|---|---|---|
| Allergic Bronchopulmonary Aspergillosis (ABPA) / Severe Asthma with Fungal Sensitisation (SAFS) | The immune system over-reacts to Aspergillus allergens, causing inflammation, mucus plugging, and airway obstruction | Too few or weak Tregs → loss of immune control |
| Chronic Pulmonary Aspergillosis (CPA) | Ongoing fungal growth with persistent inflammation and fibrosis | Excess local Treg activity may dampen antifungal defence |
| Invasive Aspergillosis (IA) | Profound immune weakness (e.g., after chemotherapy, corticosteroids, or organ transplant) | Tregs can further suppress protective antifungal responses |
⚖️ The Delicate Balance
The immune system must balance acceleration and braking:
-
Too little Treg control → allergic inflammation and tissue damage.
-
Too much Treg control → poor antifungal clearance and chronic infection.
The ideal is immune equilibrium — strong enough to fight Aspergillus, but calm enough to prevent lung injury.
đź’Š Treatments That Influence Regulatory T Cells
Several therapies already used for aspergillosis or severe asthma may influence Treg activity:
| Therapy | Possible Effect on Tregs |
|---|---|
| Corticosteroids (e.g., prednisolone) | Reduce inflammation and may increase IL-10-producing Tregs |
| Biologic therapies (omalizumab, mepolizumab, dupilumab) | Indirectly restore Treg–Th2 balance by blocking overactive allergy pathways |
| Vitamin D supplementation | Promotes stable and functional Tregs; deficiency linked with severe ABPA |
| Healthy gut microbiome (dietary fibre, probiotics) | Gut–lung axis supports Treg generation via short-chain fatty acids |
| Low-dose interleukin-2 (IL-2) therapy (research stage) | Expands Tregs selectively — now in early clinical trials for allergic and autoimmune disease |
🔬 Current Research Directions
Researchers are studying:
-
Differences in Treg profiles between ABPA, SAFS, CPA, and healthy lungs
-
How biologic therapies and antifungal drugs affect the Treg–Th2–Th17 balance
-
Whether IL-2-based immune modulation could calm allergic flares without immunosuppression
-
The influence of the airway microbiome on lung Treg activity
These studies aim for personalised immune therapy, tailoring treatment to each patient’s immune pattern.
đź’¬ Take-Home Message
Regulatory T cells are the peacekeepers of the immune system.
Their discovery — now honoured by the 2025 Nobel Prize — transformed our understanding of allergy, infection, and autoimmunity.
In aspergillosis, restoring Treg balance could one day:
-
Calm allergic inflammation in Allergic Bronchopulmonary Aspergillosis (ABPA)
-
Limit lung scarring and fibrosis in Chronic Pulmonary Aspergillosis (CPA)
-
Support better fungal control without harmful over-suppression
By understanding these immune “brakes,” researchers hope to keep both Aspergillus and the immune system under control — balanced, not overactive.
Latest News posts
News archive